MedTrace Logo

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

NCT00387582 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2014-05-06

No results posted yet for this study

Summary

This study will evaluate the clinical efficacy of intra-vitreal injections of Ranibizumab (Lucentis) in the treatment of Diabetic Macular Edema as compared to grid/focal laser.

Conditions

Interventions

DRUG

Ranibizumab (Lucentis)

Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.

PROCEDURE

Argon Laser

Argon laser at entry to trial and then per protocol for the duration of the study.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Rocky Mountain Retina Consultants

    lead OTHER

Principal Investigators

  • Roy A. Goodart, MD · Rocky Mountain Retina Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00387582 on ClinicalTrials.gov